Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3R2 | O00459 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | PIK3R5 | Q8WYR1 | 4/20 | 0.44 |
| ▸ | PIK3R3 | Q92569 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12276353 | 0.94 | MAPT (0.45) | TP53MAPTTHRBPIK3CDPIK3R2 | |
| SCHEMBL12449808 | 0.91 | RAB9A (0.50) | TP53MAPTTHRBRAB9AL3MBTL1 | |
| SCHEMBL12449813 | 0.90 | RAB9A (0.52) | TP53MAPTTHRBRAB9AL3MBTL1 | |
| SCHEMBL7605 | 0.90 | RAB9A (0.52) | TP53MAPTTHRBRAB9AL3MBTL1 | |
| SCHEMBL12276443 | 0.89 | KMT2A (0.52) | TP53MAPTTHRBPIK3CDPIK3R2 | |
| SCHEMBL13101 | 0.89 | THRB (0.46) | TP53MAPTTHRBPIK3CDPIK3R2 | |
| SCHEMBL13225 | 0.89 | PIK3CD (0.46) | TP53MAPTTHRBPIK3CDPIK3R2 | |
| SCHEMBL8490 | 0.89 | THRB (0.45) | TP53MAPTTHRBPIK3CDPIK3R2 | |
| SCHEMBL12275497 | 0.88 | PIK3CD (0.45) | TP53MAPTTHRBPIK3CDPIK3R2 | |
| SCHEMBL12275803 | 0.88 | THRB (0.44) | TP53MAPTTHRBRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2499146-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | Merck Serono S.A. (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | TP53 731/4885MAPT 965/4885THRB 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.